Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. More Details
Flawless balance sheet with acceptable track record.
Share Price & News
How has Fulgent Genetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FLGT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: FLGT's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: FLGT exceeded the US Healthcare industry which returned 16.7% over the past year.
Return vs Market: FLGT exceeded the US Market which returned 31.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Fulgent Genetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall StIs Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
1 month ago | Simply Wall StBullish: Analysts Just Made A Huge Upgrade To Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Forecasts
1 month ago | Simply Wall StIs Fulgent Genetics, Inc. (NASDAQ:FLGT) Potentially Undervalued?
Is Fulgent Genetics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: FLGT ($85.53) is trading below our estimate of fair value ($121.79)
Significantly Below Fair Value: FLGT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: FLGT is poor value based on its PE Ratio (38.2x) compared to the US Healthcare industry average (21.8x).
PE vs Market: FLGT is poor value based on its PE Ratio (38.2x) compared to the US market (21x).
Price to Earnings Growth Ratio
PEG Ratio: FLGT is poor value based on its PEG Ratio (10.1x)
Price to Book Ratio
PB vs Industry: FLGT is overvalued based on its PB Ratio (10.7x) compared to the US Healthcare industry average (3.2x).
How is Fulgent Genetics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FLGT's forecast earnings growth (3.8% per year) is above the savings rate (2%).
Earnings vs Market: FLGT's earnings (3.8% per year) are forecast to grow slower than the US market (19.5% per year).
High Growth Earnings: FLGT's earnings are forecast to grow, but not significantly.
Revenue vs Market: FLGT's revenue (2.6% per year) is forecast to grow slower than the US market (10.1% per year).
High Growth Revenue: FLGT's revenue (2.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FLGT's Return on Equity is forecast to be low in 3 years time (13.7%).
How has Fulgent Genetics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FLGT has a high level of non-cash earnings.
Growing Profit Margin: FLGT became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: FLGT has become profitable over the past 5 years, growing earnings by 65.5% per year.
Accelerating Growth: FLGT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: FLGT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (16.5%).
Return on Equity
High ROE: FLGT's Return on Equity (25.5%) is considered high.
How is Fulgent Genetics's financial position?
Financial Position Analysis
Short Term Liabilities: FLGT's short term assets ($195.6M) exceed its short term liabilities ($57.7M).
Long Term Liabilities: FLGT's short term assets ($195.6M) exceed its long term liabilities ($2.6M).
Debt to Equity History and Analysis
Debt Level: FLGT is debt free.
Reducing Debt: FLGT has not had any debt for past 5 years.
Debt Coverage: FLGT has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: FLGT has no debt, therefore coverage of interest payments is not a concern.
What is Fulgent Genetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FLGT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FLGT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FLGT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FLGT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FLGT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ming Hsieh (64 yo)
Mr. Ming Hsieh is the Founder of Fulgent Genetics, Inc. and has been its President & Chief Executive Officer since May 2016 and served as its Manager. Mr. Hsieh serves as President at Fulgent Therapeutics,...
CEO Compensation Analysis
Compensation vs Market: Ming's total compensation ($USD240.00K) is below average for companies of similar size in the US market ($USD3.64M).
Compensation vs Earnings: Ming's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||5.17yrs||US$823.48k||0.31% |
|Chief Scientific Officer & Laboratory Director||4.5yrs||US$329.70k||7.3% |
|Chief Operating Officer||no data||no data||1.68% |
|Chief Commercial Officer||1yr||no data||no data|
Experienced Management: FLGT's management team is considered experienced (4.7 years average tenure).
|Independent Director||4.5yrs||US$77.20k||0.0015% |
|Independent Director||4.5yrs||US$53.50k||no data|
|Independent Director||1.58yrs||US$120.20k||0% |
Experienced Board: FLGT's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: FLGT insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.6%.
Fulgent Genetics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Fulgent Genetics, Inc.
- Ticker: FLGT
- Exchange: NasdaqGM
- Founded: 2011
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$2.076b
- Shares outstanding: 24.27m
- Website: https://www.fulgentgenetics.com
Number of Employees
- Fulgent Genetics, Inc.
- 4978 Santa Anita Avenue
- Suite 205
- Temple City
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|FLGT||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Sep 2016|
|7F0||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2016|
|FLGT *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Sep 2016|
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/03/05 01:39|
|End of Day Share Price||2021/03/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.